In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for
atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30
Revitalist Lifestyle and Wellness LTD. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) recently announced a new joint venture partnership with Wake Network, Inc.
Psychedelic biotechnology company Bright Minds Biosciences recently announced that it has dosed the first patient in a Phase I trial (NCT 05397041)
Drug discovery and development company Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced today the company has identified three additional families